TWG-07-148
TWG-07-148 is a Trametinib (HY-10999) derivative and a selective inhibitor of ARAF/MEK1. TWG-07-148 covalently targets the ARAF-unique Cys514 residue and blocks ARAF-driven MEK activation. TWG-07-148 allosterically binds MEK and prevents RAF-mediated MEK activation. TWG-07-148 induces cell cycle arrest and inhibits the proliferation of BRAF- and KRAS-mutant cancer cell lines. TWG-07-148 shows sustained inhibition of ERK phosphorylation in ARAF-driven cells. TWG-07-148 can be used for cancer-related research.
For research use only. We do not sell to patients.
- CAS No.: 2665700-96-7
- Formula: C27H23FIN5O4
- Molecular Weight:627.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
MEK1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
5.5 nM
|
Inhibition of proliferation of Ba/F3 cells expressing ARAF S214A assessed as viability by CellTiter-Glo after 72 hrs incubation.
Inhibition of proliferation of Ba/F3 cells expressing ARAF S214A assessed as viability by CellTiter-Glo after 72 hrs incubation.
|
42912982 |
| A-375 | IC50 |
6.8 nM
|
Antiproliferative activity against human BRAF V600E mutant A375 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
Antiproliferative activity against human BRAF V600E mutant A375 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
|
42912982 |
| HT-29 | IC50 |
7.9 nM
|
Antiproliferative activity against human BRAF V600E mutant HT29 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
Antiproliferative activity against human BRAF V600E mutant HT29 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
|
42912982 |
| NCI-H2122 | IC50 |
20.5 nM
|
Antiproliferative activity against human KRAS mutant H2122 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
Antiproliferative activity against human KRAS mutant H2122 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
|
42912982 |
| HCT-116 | IC50 |
47.9 nM
|
Antiproliferative activity against human KRAS mutant HCT116 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
Antiproliferative activity against human KRAS mutant HCT116 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
|
42912982 |
| A549 | IC50 |
36.6 nM
|
Antiproliferative activity against human KRAS mutant A549 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
Antiproliferative activity against human KRAS mutant A549 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
|
42912982 |
| PC-9 | IC50 |
136.8 nM
|
Antiproliferative activity against human EGFR exon 19 deletion PC9 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
Antiproliferative activity against human EGFR exon 19 deletion PC9 cells assessed as viability by CellTiter-Glo after 72 hrs incubation.
|
42912982 |
In Vitro
TWG-07-148 (0.01-1 μM) dose-dependently inhibits pMEK and pERK in ARAFS214A, BRAFS365A, and CRAFS259A Ba/F3 cells as well as in A375 and HT29 cells[1].
TWG-07-148 inhibits ARAF-MEK1 with an IC50 of 20.9 nM and inhibits ARAFC514A-MEK1 with an IC50 of 10 nM[1].
TWG-07-148 inhibits ARAFS214A Ba/F3 cell proliferation with an IC50 of 5.5 nM, and inhibits ARAFS214A/C514A Ba/F3 cell proliferation with an IC50 < 1 nM[1].
TWG-07-148 (50 nM; 16 h) causes sustained pERK inhibition after washout in ARAFS214A Ba/F3 cells compared with BRAFS365A and CRAFS259A cells[1].
TWG-07-148 (1 μM) exhibits excellent selectivity in a radioactivity-based panel comprising 70 kinases[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ARAF S214A, BRAF S365A, and CRAF S259A Ba/F3 cells
-
Concentration:50 nM
-
Incubation Time:16 h; washout at 0, 2, 6, and 24 h
-
Result:Produced prolonged inhibition of ERK phosphorylation after washout in ARAFS214A Ba/F3 cells compared with BRAFS365A and CRAFS259A Ba/F3 cells.
-
Cell Line:ARAF S214A, BRAF S365A, and CRAF S259A Ba/F3 cells and A375 and HT29 cancer cell lines
-
Concentration:0.1 and 1 μM
-
Incubation Time:48 h
-
Result:Significantly increased the fraction of cells in G0/G1 in ARAFS214A, BRAFS365A, and CRAFS259A Ba/F3 cells.
A similar G0/G1 block was observed in A375 and HT29 cells.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUClast | AUCINF_obs | CL_obs | MRTINF_obs | Vss_obs | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 1 mg/kg | i.v. | 1.45 h | 0.08 h | 1855.73 ng/mL | 1115.23 ng·h/mL | 1130.65 ng·h/mL | 14.76 mL/min/kg | 1.13 h | 1.00 L/kg | / |
| Mice[1] | 3 mg/kg | p.o. | 1.55 h | 0.25 h | 467.23 ng/mL | 948.16 ng·h/mL | 949.59 ng·h/mL | 53.91 mL/min/kg | / | / | 28 % |
Chemical Information
-
CAS No. 2665700-96-7
-
Molecular Weight 627.41
-
Formula C27H23FIN5O4
-
SMILES
C=CC(NC1=CC=CC(N(C(C(C(N2C3CC3)=O)=C(NC4=CC=C(I)C=C4F)N5C)=C(C)C5=O)C2=O)=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- TWG-07-148
- 2665700-96-7
- MEK
- PERK
- Drug Derivative
- Mitogen-activated protein kinase kinase
- MAPKK
- MAP2K
- Protein kinase R-like endoplasmic reticulum kinase
- PKR-like endoplasmic reticulum kinase
- Drug derivative
- ARAF
- BRAF-mutant cancer
- ERK phosphorylation
- KRAS-mutant cancer
- MEK activation
- MEK1
- cancer
- cell cycle arrest
- cysteine
- proliferation
- Inhibitor
- inhibitor
- inhibit